title: Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.
abstract: Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure. Therefore, investigations on novel therapeutic targets are of fundamental importance. Deregulation of epigenetic mechanisms underlying chromatin modifications during stem cell differentiation has been suggested to contribute to soft tissue sarcoma pathogenesis. One of the main elements in this scenario is enhancer of zeste homolog 2 (EZH2), a methyltransferase belonging to the Polycomb group proteins. EZH2 catalyzes histone H3 methylation on gene promoters, thus repressing genes that induce stem cell differentiation to maintain an embryonic stem cell signature. EZH2 deregulated expression/function in soft tissue sarcomas has been recently reported. In this review, an overview of the recently reported functions of EZH2 in soft tissue sarcomas is given and the hypothesis that its expression might be involved in soft tissue sarcomagenesis is discussed. Finally, the therapeutic potential of epigenetic therapies modulating EZH2-mediated gene repression is considered.
authors: Department of Oncohematology, IRCCS, Ospedale Pediatrico Bambino Gesù, Roma, Italy. roberta.ciarapica@yahoo.com
authors: Roberta
authors: R
authors: Ciarapica
authors: Lucio
authors: L
authors: Miele
authors: Antonio
authors: A
authors: Giordano
authors: Franco
authors: F
authors: Locatelli
authors: Rossella
authors: R
authors: Rota
references: J Clin Oncol. 2009 Dec 1;27(34):5800-7
references: 19786654
references: Cancer Res. 2008 Jun 1;68(11):4303-10
references: 18519690
references: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
references: 14500907
references: Lancet. 2006 Oct 14;368(9544):1329-38
references: 17046465
references: Cancer Lett. 2009 Jul 8;279(2):126-36
references: 19008039
references: Med Pediatr Oncol. 2001 Aug;37(2):90-6
references: 11496345
references: Curr Stem Cell Res Ther. 2010 Mar;5(1):63-73
references: 19807660
references: Clin Cancer Res. 2010 Aug 15;16(16):4077-83
references: 20547696
references: Lancet Oncol. 2009 Mar;10(3):223-32
references: 19230772
references: J Clin Oncol. 2009 Jul 1;27(19):3154-60
references: 19451429
references: Cancer. 2011 Aug 1;117(15):3468-75
references: 21287536
references: Expert Rev Anticancer Ther. 2010 Feb;10(2):249-60
references: 20132000
references: Mol Cell Biol. 2007 Jun;27(12):4374-87
references: 17438126
references: Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5324-9
references: 19289832
references: Cancer. 2011 Apr 15;117(8):1661-9
references: 21472713
references: Int J Clin Exp Pathol. 2010 Apr 23;3(4):416-28
references: 20490332
references: Cancer Sci. 2010 Feb;101(2):355-62
references: 19860841
references: Annu Rev Genet. 2004;38:413-43
references: 15568982
references: Genes Dev. 2004 Nov 1;18(21):2627-38
references: 15520282
references: Breast Cancer Res. 2009;11(5):108
references: 19804613
references: Clin Cancer Res. 2003 Nov 15;9(15):5749-55
references: 14654560
references: Lancet Oncol. 2010 Feb;11(2):129-35
references: 20036194
references: Mutat Res. 2008 Dec 1;647(1-2):21-9
references: 18723033
references: J Clin Oncol. 2009 Jul 1;27(19):3126-32
references: 19451427
references: Int J Cancer. 2005 Sep 20;116(5):784-92
references: 15849726
references: Mol Cell. 2009 Oct 9;36(1):61-74
references: 19818710
references: Nature. 2002 Oct 10;419(6907):624-9
references: 12374981
references: Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1859-64
references: 15684044
references: Genes Dev. 2007 May 1;21(9):1050-63
references: 17437993
references: Nat Rev Cancer. 2006 Nov;6(11):846-56
references: 17060944
references: Clin Cancer Res. 2009 Sep 15;15(18):5910-6
references: 19723647
references: Breast Cancer Res Treat. 2011 May;127(1):109-19
references: 20556507
references: Cancer Res. 2008 Apr 1;68(7):2176-85
references: 18381423
references: Nature. 2006 Feb 16;439(7078):871-4
references: 16357870
references: Blood. 2009 Sep 24;114(13):2764-73
references: 19546476
references: Drugs R D. 2010;10(3):165-78
references: 20945947
references: PLoS One. 2010 Sep 13;5(9):e12710
references: 20856924
references: Drug Des Devel Ther. 2010 Sep 24;4:221-9
references: 20957213
references: Oncogene. 1999 Apr 29;18(17):2739-46
references: 10348348
references: Cell. 2007 Feb 23;128(4):735-45
references: 17320510
references: Curr Opin Mol Ther. 2010 Jun;12(3):361-71
references: 20521225
references: Cancer Cell Int. 2008 Nov 17;8:16
references: 19014694
references: J Clin Oncol. 2010 Mar 1;28(7):1240-6
references: 20124188
references: Cancer Biol Ther. 2009 May;8(10):939-50
references: 19279403
references: J Pathol. 2007 Jun;212(2):143-51
references: 17471488
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: PLoS One. 2010 Jul 09;5(7):e11483
references: 20634887
references: Curr Oncol Rep. 2010 Jul;12(4):261-5
references: 20464642
references: Cell Cycle. 2009 Jan 1;8(1):172-5
references: 19106613
references: J Natl Cancer Inst. 2009 Oct 7;101(19):1300-1
references: 19755677
references: J Clin Oncol. 2010 May 1;28(13):2151-8
references: 20351326
references: Oncogene. 1999 Sep 20;18(38):5340-8
references: 10498887
references: Nat Rev Drug Discov. 2006 Jan;5(1):37-50
references: 16485345
references: Cancer Res. 2006 Oct 1;66(19):9474-82
references: 17018603
references: Neuropathol Appl Neurobiol. 2011 Jun;37(4):381-94
references: 20946108
references: Stem Cells. 2007 Oct;25(10):2498-510
references: 17600113
references: J Biol Chem. 2008 Apr 11;283(15):9836-43
references: 18281287
references: Int J Cancer. 2011 Oct 15;129(8):1963-9
references: 21154746
references: Cancer Cell. 2008 Nov 4;14(5):369-81
references: 18977326
references: EMBO J. 1997 Jun 2;16(11):3219-32
references: 9214638
references: J Clin Oncol. 2008 Feb 1;26(4):626-32
references: 18235122
references: Oncogene. 2008 Mar 27;27(14):2015-26
references: 17922033
references: Future Oncol. 2009 Nov;5(9):1449-75
references: 19903072
references: Blood. 2009 Sep 24;114(13):2733-43
references: 19638619
references: Cell Cycle. 2009 Jul 1;8(13):1991-6
references: 19502792
references: Cancer Res. 2006 Jul 15;66(14):6936-46
references: 16849537
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: Ann Hematol. 2011 Apr;90(4):379-87
references: 20922525
references: Expert Opin Emerg Drugs. 2010 Jun;15(2):237-48
references: 20465449